Fly News Breaks for June 14, 2019
Jun 14, 2019 | 08:29 EDT
Maxim analyst Jason McCarthy initiated Achieve Life Sciences (ACHV) with a Buy rating and a price target of $6, citing the company's development of a "de-risked" smoking cessation aid cytisinicline. The analyst notes that cytisinicline has been in the Eastern European market since the 1970's but has also recently gained "proof of concept" data with a positive phase 2b study of 54% abstinence following 3mg daily intake vs. 16% for placebo. McCarthy adds that Pfizer's (PFE) competing Chantix generated $838M in revenue in FY18 but covered only about 3% of the U.S. smoking population.
News For ACHV;PFE From the Last 2 Days